Flexible analytics are valuable tools to inform the management of costs and outcomes for therapies such as glucagon-like peptide-1 (GLP-1) drugs, having a significant impact on payer spending and trend. This paper summarizes central themes and provides illustrative examples from Milliman’s GLP-1 Impact Dashboard suite of analytics to facilitate the strategic management of GLP-1-related care.

Highlights

• There is an increased need for thorough data analysis to understand the impact on specific populations. This paper provides an example from Milliman’s GLP-1 Impact Dashboard of a sample cohort of non-diabetic patients with obesity.
• In this paper, we discuss how Milliman's dashboard can facilitate longitudinal analyses of patients with chronic conditions, and offer insights into benchmarks and outcomes.
• Key features of the dashboard include insights into patient medication adherence, trends in healthcare spending and utilization, and a longitudinal view of the impact on the total cost of care, both before and after pharmacy rebates.
• The dashboard also allows for the integration of client-specific data, enabling stakeholders to evaluate their own experiences and performance.